Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Top Cited Papers
- 10 August 2015
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 139 (1), 10-16
- https://doi.org/10.1016/j.ygyno.2015.08.004
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 19 references indexed in Scilit:
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- Ten-Year Relative Survival for Epithelial Ovarian CancerObstetrics and Gynecology, 2012
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerThe New England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerThe New England Journal of Medicine, 2011
- Bevacizumab toxicities and their management in ovarian cancerGynecologic Oncology, 2010
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- A Confidence Interval for the Median Survival TimeBiometrics, 1982